Company
Every investor coverage indicates participated in a round Emyria raised.
Investors whose own portfolio pages list Emyria, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Tenmile | its portfolio page ↗ |
Companies Emyria acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Emyria. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Therapeutic psychedelics biotech Emyria has banked $2.5 million via a share placement co-led by Sixty Two Capital and Taylor Collison, with follow-on from Andrew Forrest's Tenmile, funding MDMA- and psilocybin-assisted therapy and cannabinoid trials.
Biotech Aravax has received a US$20 million Series B commitment from Brandon Capital and Tenmile to advance its peanut allergy therapy PVX108 into Phase 2 trials.
Also Brandon Capital portfolio·Startup Daily·Startup News (WA)·Techboard·Startup Daily
Andrew Forrest's private investment company Tattarang is launching Tenmile, a Perth-based $250 million health-tech venture fund that has already backed Emyria and Carina Biotech and partnered with Rock Health.